Big Pharma Scrambles for a Piece of the Vaccine Pie
Glaxo is the latest to get H1N1 vaccine approval.
(Editor's Note: Also read our Viral Threats package.)
A slew of pharmaceutical companies have scooped up smaller biotechs and vaccine makers in an effort to bolster their pathetic showing in the arena this year.
Pfizer (PFE) slapped down a hefty $68 billion for Wyeth to secure what many industry insiders consider to be the most valuable research team developing vaccines. The acquisition, which was completed in October, gives Pfizer access to the top-selling pneumococcal vaccine for children, Prevnar, among others.
Abbott Laboratories (ABT) announced in September that it plans to drop a whopping $6.6 billion for the Belgium-based Solvay to get its hand on its flu vaccine, which brought in $201 million in sales in 2008. The deal has yet to close.
Johnson & Johnson (JNJ) is also jumping into the vaccination craze with the purchase of an 18% stake in Crucell for $444 million. The Dutch company entered into a deal with Johnson & Johnson concerning its flu vaccine.
Not all of Big Pharma is buying its way into the inoculation industry: Merck (MRK), Novartis (NVS), and GalxoSmithKline (GSK) are already major players in vaccines.
Glaxo got approval from the US Food and Drug Administration on Wednesday to make 7.6 million doses of its unadjuvanted H1N1 vaccine by the end of the year -- only a small portion of the doses that will be needed. The British company makes an adjuvanted version (a vaccine with add-ins that boost the immune response) of the vaccine in Europe.
Merck got approval for its human papillomavirus vaccine in 2006. The vaccine was originally produced to prevent the infection that causes cervical cancer in girls and young women. It was approved in October by the FDA for the treatment of genital warts caused by HPV in boys and young men.
The pharma giant also produces vaccines for measles, mumps, rubella, as well as hepatitis A and B. Merck saw revenues of $1.2 billion for its vaccines and infectious disease drugs during the third quarter of 2009.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.
Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Daily Recap Newsletter